​

Semaglutide Shows Promise in Treating Metabolic Dysfunction-Associated Steatohepatitis

Topic: DIABETES & ENDOCRINOLOGY, GASTROINTESTINAL
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 30th, 2025
Currently, there is no approved treatment for metabolic dysfunction-associated steatohepatitis. With the condition heavily linked to obesity and diabetes, a study was funded by Novo Nordisk to examine the usage of semaglutide in managing liver health in patients with liver fibrosis and steatohepatitis.

Semaglutide Found to Lower Cardiovascular Risk in Patients with Type 2 Diabetes​

Topic: DIABETES & ENDOCRINOLOGY, CARDIOLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 27th, 2025
Those affected with type 2 diabetes experience an elevated risk of cardiovascular disease. Previous study examining the glycemic control of semaglutide, a GLP-1 receptor agonist, had found that it also reduced the risk of cardiovascular disease. To fully explore this relationship, Novo Nordisk had sponsored a study to examine the effect of semaglutide on cardiovascular health in patients with type 2 diabetes.

Early Antiviral Therapy in Chronic Hepatitis B Shows Promise in Preventing Liver Complications

Topic: INFECTIOUS DISEASE​​, GASTROINTESTINAL
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 25th, 2025
Chronic hepatitis B infection is a well-established risk factor for liver cirrhosis and hepatocellular carcinoma. While antiviral medications are effective in managing the disease, current treatment guidelines typically recommend delaying initiation until elevated liver enzymes are detected. However, recent observational data suggest that viremia alone may contribute to increased cancer risk, regardless of enzyme levels. In response, the Government of South Korea, in collaboration with Gilead, funded a study to evaluate the benefits of early antiviral intervention in patients with normal liver enzyme levels.

Comparing the Ceftolozane–Tazobactam & Ceftazidime–Avibactam Combinations in Treating Multidrug Resistant Pseudomonas aeruginosa

Topic: INFECTIOUS DISEASE​​, RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 23rd, 2025
Pseudomonas aeruginosa is a prevalent bacterial pathogen, and infections caused by multidrug-resistant strains pose a significant clinical threat. While the antibiotic combinations ceftolozane–tazobactam and ceftazidime–avibactam have shown efficacy against resistant strains, limited data exist comparing their performance across different clinical scenarios. To address this gap and support the refinement of treatment guidelines, a study funded by Merck was conducted to evaluate their relative effectiveness.

Managing Pulmonary Arterial Hypertension with Sotatercept

Topic: CARDIOLOGY, RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 20th, 2025
Pulmonary arterial hypertension, if left untreated or poorly controlled, can progress to right ventricular failure and ultimately lead to death. While current therapies can slow disease progression, they have not demonstrated a consistent ability to prevent critical outcomes such as hospitalization, lung transplantation, or mortality. To address this unmet need, a study funded by Merck investigated the use of sotatercept as a potential disease-modifying therapy for PAH.

Sofosbuvir-Based Therapies for Children With Hepatitis C​

Topic: INFECTIOUS DISEASE​​, PEDIATRIC, GASTROINTESTINAL
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 18th, 2025
Hepatitis C treatments that are effective in adults—such as pegylated interferon and ribavirin—have been associated with developmental complications in pediatric populations. Although the World Health Organization recommends the use antiviral, the long-term safety of these therapies in children remains uncertain. To address this gap, a study funded by Gilead Sciences was conducted to evaluate the long-term safety and efficacy of sofosbuvir in children.

Nirsevimab Demonstrates Durable Efficacy in Preventing RSV-Related Hospitalizations in Children

Topic: INFECTIOUS DISEASE​​, PEDIATRIC, RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 16th, 2025
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Nirsevimab, a monoclonal antibody that targets the RSV F protein to block viral fusion, has previously shown promise in preventing infection. A recent study funded by AstraZeneca and Sanofi has now reported on the long-term protective effects of nirsevimab.

Impact of Long-Term Tiotropium Usage on Dementia Risk

Topic: NEUROLOGY, RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 13th, 2025
Medications that interfere with acetylcholine signaling have been linked to cognitive decline. Long-acting antimuscarinic agents like tiotropium, commonly prescribed for chronic obstructive pulmonary disease (COPD), have known anticholinergic effects, but their impact on neurological function remains unclear. Previous studies on this topic have been limited by poor design. To address this gap, a study funded by the Brain Canada Foundation examined whether tiotropium use is associated with an increased risk of developing dementia.

Oral Orexin Agonist Oveporexton Shows Promise for Narcolepsy Without Liver Toxicity​

Topic: NEUROLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 11th, 2025
The loss of orexin-producing neurons in the hypothalamus is the primary driver of narcolepsy, particularly type 1. While existing treatments focus on alleviating symptoms—such as promoting daytime wakefulness and reducing cataplexy—they do not target the underlying orexin deficiency. Previous attempts to develop orexin receptor agonists have been hampered by the need for intravenous delivery and concerns over liver toxicity. With funding from Takeda, a new study explored the use of oveporexton, a blood-brain barrier–permeable, orally administered orexin agonist, for the treatment of narcolepsy.

Positive Results for Brexpiprazole in Youth Schizophrenia

Topic: PSYCHIATRY, PEDIATRIC
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 6th, 2025
Schizophrenia in children often presents with more severe symptoms and a poorer prognosis compared to adults. While there are effective antipsychotic treatments available for children and adolescents, these agents tend to carry higher risks in younger patients. Recent studies have suggested that beyond dopamine, other monoamine neurotransmitters—such as norepinephrine and serotonin—also contribute to the pathophysiology of schizophrenia. With funding from Otsuka Pharmaceutical, a study was conducted to evaluate the use of brexpiprazole in managing pediatric schizophrenia.

Lorundrostat Shows Promise in Drug-Resistant Hypertension

Topic: CARDIOLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 4th, 2025
Despite the use of multidrug regimens, many patients with hypertension continue to struggle with blood pressure control. Emerging research suggests that aldosterone dysregulation may be a key driver of treatment-resistant hypertension. With funding from Mineralys Therapeutics, a study was conducted to evaluate lorundrostat, an aldosterone synthase inhibitor, for managing blood pressure in this population.

BCG Revaccination Fails to Prevent TB Infection in Adolescents​

Topic: INFECTIOUS DISEASE
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on June 2nd, 2025
Tuberculosis continues to pose a major public health burden in Vietnam and around the world, causing over 1 million deaths annually. Although the bacille Calmette–Guérin (BCG) vaccine has been used for decades to prevent infection, its protective effect diminishes over time. There has been growing interest in exploring whether revaccination with BCG could restore immunity. With support from the Bill & Melinda Gates Foundation, a study was conducted to evaluate the impact of BCG revaccination on tuberculosis prevention.

Direct Oral Anticoagulants vs. Vitamin K Antagonists in Cerebral Venous Thrombosis

Topic: NEUROLOGY, CARDIOLOGY​​
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 30th, 2025
The optimal anticoagulation strategy for patients with cerebral venous thrombosis remains a topic of ongoing debate. While direct oral anticoagulants are more convenient for patients and have been associated with lower rates of intracranial hemorrhage, vitamin K antagonists remain more cost-effective. Additionally, vitamin K antagonists are associated with lower gastrointestinal bleeding risk, and are preferred in patients with mechanical heart valves. Given the lack of consensus, a multinational observational study was undertaken with support from the Netherlands Thrombosis Foundation.

Anti-IL-5 Therapy, Mepolizumab, Shows Promise in COPD Management​

Topic: ALLERGY & IMMUNOLOGY, RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 28th, 2025
Eosinophilic inflammation plays a significant role in chronic obstructive pulmonary disease (COPD), with interleukin-5 (IL-5) driving eosinophil maturation and activation. To evaluate a targeted approach, GlaxoSmithKline sponsored a study examining the efficacy of mepolizumab—an anti-IL-5 monoclonal antibody—in managing COPD.

Lepodisiran, a Small Interfering Therapy Significantly Lowers Lipoprotein(a) Level

Topic: CARDIOLOGY​​​
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 26th, 2025
Lipoprotein(a) [Lp(a)] is a key component in the formation of cholesterol-transporting LDL particles. Elevated serum concentrations of Lp(a) have been linked to a higher risk of cardiovascular mortality. In efforts to address this risk factor, Eli Lilly sponsored a study evaluating the effectiveness of lepodisiran, a novel therapy aimed at lowering Lp(a) levels.

Tamuzimod, an S1PR1 Inhibitor, Shows Promise in Reducing Ulcerative Colitis Symptoms

Topic: ALLERGY & IMMUNOLOGY, GASTROINTESTINAL
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 23rd, 2025
Chronic inflammation of the colonic epithelium underlies ulcerative colitis, a condition that can significantly impair quality of life and elevate the long-term risk of colorectal cancer. While various treatments are available, many fall short in preventing disease relapse or carry undesirable side effects. To explore new therapeutic options, a study funded by Ventyx Biosciences evaluated the potential of tamuzimod for managing ulcerative colitis.

Cytisinicline Shows Promise as a Well-Tolerated and Effective Aid for Smoking Cessation​

Topic: RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 21st, 2025
Smoking is one of the most prevalent risk factors contributing to millions of preventable deaths each year. While several smoking cessation aids such as bupropion and varenicline are currently available, their limited long-term effectiveness and notable side effect profiles highlight the need for new alternatives. Backed by funding from the biotechnology company Achieve Life Sciences, a clinical trial was conducted to evaluate the efficacy of cytisinicline in reducing nicotine cravings.

Baloxavir Shows Promise in Reducing Household Transmission of Influenza

Topic: RESPIRATORY, INFECTIOUS DISEASE
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 19th, 2025
While often regarded as a seasonal inconvenience for healthy adults, influenza can pose a serious, even fatal, threat to children, the elderly, and immunocompromised individuals. Each flu season typically involves the circulation of four distinct influenza strains, all of which are included in the annually updated vaccine. However, because the vaccine formulation relies on predictive modeling of which strains will dominate, its effectiveness varies from year to year and can be suboptimal. Although antivirals for influenza are available, there is limited conclusive evidence supporting their ability to reduce transmission. In pursuit of new options, Roche sponsored a study to evaluate the potential of baloxavir to lower influenza contagiousness.​

Brensocatib Reduces Exacerbation Risk and Slows Lung Function Decline in Patients with Bronchiectasis

Topic: RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 16th, 2025
Patients with bronchiectasis typically present with a chronic cough and excessive sputum production. The progressive decline in lung function associated with this disease is largely driven by neutrophil-mediated inflammation and damage to the mucociliary membrane. Current clinical guidelines generally recommend the use of mucoactive agents to alleviate symptoms and antibiotics to prevent bacterial infections. Recently, a study funded by Insmed and published in The New England Journal of Medicine examined the use of brensocatib, a drug aimed at managing bronchiectasis by inhibiting neutrophil activity.​

Evaluating Tecovirimat in Hospitalized Patients With Monkeypox

Topic: INFECTIOUS DISEASE
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 14th, 2025
Since its global spread during the 2022 outbreak, monkeypox has been effectively controlled in most parts of the world. However, cases have continued to rise in sub-Saharan Africa, particularly in the Democratic Republic of Congo (DRC). Currently, there is no approved specific antiviral treatment for monkeypox. In response to the growing burden, the United States National Institute of Allergy and Infectious Diseases (NIAID) partnered with the Congolese Ministry of Health to investigate the efficacy of tecovirimat as a treatment for monkeypox infection.

B-Cell Depletion With Obinutuzumab & Standard Therapy in Lupus Nephritis

Topic: ALLERGY & IMMUNOLOGY, UROLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 12th, 2025
Lupus nephritis is a severe autoimmune condition in which the immune system produces antibodies that mistakenly target kidney cells, impairing their filtration function. Although new therapies such as belimumab and voclosporin have recently been approved by regulatory agencies in the United States and Europe, these treatments have shown limitations in clinical outcomes. Consequently, there remains an urgent need for alternative therapeutic options. With funding from Roche, a study was conducted to evaluate the efficacy and safety of obinutuzumab in the treatment of lupus nephritis.

Dapagliflozin Reduces Heart Failure Worsening in Elderly Patients with Severe Aortic Stenosis​

Topic: CARDIOLOGY​​​
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 9th, 2025
Many clinical guidelines in both the United States and Europe recommend the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for patients with heart failure, regardless of diabetes status. However, individuals with severe valvular heart disease requiring transcatheter aortic-valve implantation have largely been excluded from these studies. To address this gap, a study funded by the Carlos III Health Institute in Spain was conducted to evaluate the use of SGLT2 inhibitors in patients with severe aortic stenosis.

Reduced-Dose Apixaban Effectively Prevents Venous Thromboembolism in Cancer Patients

Topic: ONCOLOGY, CARDIOLOGY​​​
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 7th, 2025
Patients with cancer face a significantly higher risk of venous thromboembolism compared to their healthy counterparts. Although many current guidelines recommend continued anticoagulation throughout the duration of cancer, prolonged therapy increases the risk of bleeding complications. To explore an optimal dosing strategy, a study funded by Bristol-Myers Squibb was conducted to evaluate the efficacy and safety of different apixaban dosing regimens in preventing thromboembolism among cancer patients.

Efficacy of Gepotidacin Versus Nitrofurantoin for the Treatment of Lower Urinary Tract Infections

Topic: UROLOGY, INFECTIOUS DISEASE​
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 5th, 2025
Lower urinary tract infections are extremely common, with approximately half of all women worldwide reporting at least one episode during their lifetime. Although these infections are generally manageable with antibiotics, past misuse has contributed to the growing problem of antimicrobial resistance, highlighting the need for new treatment options. Gepotidacin is a novel therapeutic agent, and GlaxoSmithKline sponsored a study to compare its effectiveness to that of nitrofurantoin in treating urinary tract infections.

Lenacapavir Outperforms Daily Emtricitabine–Tenofovir for HIV Prevention

Topic: INFECTIOUS DISEASE
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on May 2nd, 2025
Although the global number of new HIV infections is declining, infections among men who have sex with men and transgender women are rising. Pre-exposure prophylaxis (PrEP) is an effective method to prevent HIV transmission, but it requires consistent adherence to maintain its efficacy. To explore alternative prevention strategies, a study funded by Gilead Sciences evaluated the use of lenacapavir for HIV prevention.

Managing ESR1-Mutated ER-Positive Breast Cancer with Imlunestrant & Abemaciclib​

Topic: ONCOLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 30th, 2025
Estrogen receptor (ER)-positive breast cancer can be managed with ER antagonists like fulvestrant. However, fulvestrant’s requirement for intramuscular injection complicates treatment, necessitating clinic visits and limiting its convenience. Furthermore, its efficacy is reduced in patients with ESR1 mutations in the estrogen receptor. Imlunestrant is a newer, orally available ER antagonist. To evaluate its effectiveness, Eli Lilly sponsored a study combining imlunestrant with abemaciclib in managing ER-positive, HER2-negative breast cancer.

Tezepelumab Shows Promise in Reducing Nasal Polyps and Symptoms in Chronic Rhinosinusitis

Topic: ALLERGY & IMMUNOLOGY, RESPIRATORY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 28th, 2025
Chronic rhinosinusitis with nasal polyps is typically managed with glucocorticoids and biologic therapies targeting various components of the type 2 inflammatory pathway. However, current treatments are not universally effective, highlighting the need for therapies that act through alternative mechanisms. To address this gap, AstraZeneca sponsored a study to evaluate the efficacy of tezepelumab in treating this condition.

Muvalaplin Effectively Lowers Lipoprotein(a) in Cardiovascular Patients

Topic: CARDIOLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 25th, 2025
Lipoprotein(a) is critical for packaging and transporting cholesterol in the bloodstream via low-density lipoproteins. Elevated levels of lipoprotein(a) heighten the risk of atherosclerotic cardiovascular disease by promoting plaque buildup. With funding from Eli Lilly, a study was undertaken to evaluate the efficacy of Muvalaplin in controlling lipoprotein(a) levels.

Comparing Oral Glucose-Lowering Agents and Insulin in Gestational Diabetes

Topic: DIABETES & ENDOCRINOLOGY, OBGYN
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 23rd, 2025
Insulin has long been the standard therapy for controlling blood glucose in women with gestational diabetes. While oral agents like metformin and glyburide offer a more convenient alternative due to their ease of administration, the American Diabetes Association has advised against their use because of limited data on the long-term safety for offspring. To address this issue, the Australian National Health and Medical Research Council sponsored a study comparing the effectiveness of oral glucose-lowering agents with insulin for managing gestational diabetes.

Preventing Recurrent Bacterial Vaginosis by Treating Male Sexual Partners with Combined Oral and Topical Antibiotics​

Topic: INFECTIOUS DISEASE, OBGYN
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 21st, 2025
Bacterial vaginosis is marked by a disruption of the normal vaginal microbiota, and previous research suggests that the penile microbiome of a male partner may predict the occurrence of bacterial vaginosis in the female partner. Funded by the National Health and Medical Research Council of Australia, a study was conducted to evaluate whether treating the male partner could help prevent recurrence in women.

Simvastatin and Rifaximin Combination Therapy to Manage Decompensated Liver Cirrhosis

Topic: GASTROINTESTINAL
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 18th, 2025
Decompensated liver cirrhosis represents the most advanced stage of liver damage, marked by extensive scarring and significantly reduced liver function. This condition can ultimately progress to acute liver failure and death, and there are currently no therapies available to prevent its progression. Funded by the European Union, a study was conducted to evaluate the use of simvastatin and rifaximin in managing liver cirrhosis.

Comparative Efficacy of 7-Day versus 14-Day Antibiotic Regimens for Bloodstream Infections

Topic: INFECTIOUS DISEASE
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 16th, 2025
Bloodstream infections can be treated with antibiotics, but there is little consensus on the optimal treatment duration. A short-term, 7-day regimen may not be sufficient to eradicate the bacteria and might lead to the selection of resistant strains, while a longer, 14-day regimen could be excessive—resulting in adverse events, secondary infections, increased resistance pressure on non-pathogens, and unnecessary resource use. To answer this question, the Canadian Institutes of Health Research sponsored a study to determine the optimal treatment duration.

Treating Chronic Spontaneous Urticaria by Blocking Histamine Release with Remibrutinib

Topic: DERMATOLOGY, ​ALLERGY & IMMUNOLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 14th, 2025
Chronic spontaneous urticaria is an allergic condition marked by unpredictable itching and hives, with no identifiable trigger. This allergic reaction results from mast cell degranulation. While second-generation H1 antihistamines are the most commonly prescribed treatment, up to 75% of patients may not respond even at maximum doses. Novartis sponsored a study to evaluate the effectiveness of remibrutinib, a BTK inhibitor, in managing urticaria.

High-Dose Vitamin D Supplementation to Manage and Prevent Multiple Sclerosis

Topic: ALLERGY & IMMUNOLOGY, NEUROLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 11th, 2025
In patients with multiple sclerosis, low levels of vitamin D are linked to an increased risk of relapse, a greater disease burden, and more brain lesions. Vitamin D modulates the immune system by reducing lymphocyte differentiation and limiting the migration of immune cells across the blood-brain barrier. Based on this hypothesis, a study funded by the French Ministry of Health was conducted to assess the potential of vitamin D in managing multiple sclerosis and preventing relapses.

Long-Term Tirzepatide Therapy Yields Significant Weight Loss and Cardiometabolic Benefits​

Topic: DIABETES & ENDOCRINOLOGY, CARDIOLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 9th, 2025
Obesity is closely linked to the development of type 2 diabetes, a condition marked by significant beta cell dysfunction and insulin resistance. Weight management—whether through pharmacological interventions or lifestyle changes—has been proven to lower the risk of diabetes. Numerous studies have highlighted the weight loss benefits of tirzepatide, and a study funded by Eli Lilly has explored its potential for treating obesity and preventing diabetes.

Using Lactin-V Probiotic to Prevent Recurrent Bacterial Vaginosis after Metronidazole Treatment

Topic: INFECTIOUS DISEASE, OBGYN
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 7th, 2025
Bacterial vaginosis is a common condition that many women experience. Although it can be treated with antibiotics, recurrences are frequent, and if not managed effectively, the condition can lead to secondary infections and subsequent reproductive complications, imposing significant physical and emotional burdens. Funded by the United States National Institutes of Health, a study was conducted to explore the use of an intravaginal probiotic to prevent recurrent bacterial vaginosis.

Sipavibart vs. Tixagevimab/Cilgavimab for COVID-19 Prevention in Immunocompromised Patients

Topic: COVID-19
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 4th, 2025
Although COVID-19 vaccines have been highly effective, many immunocompromised individuals are unable to benefit from their protection. To address this, antibody combinations such as tixagevimab and cilgavimab—targeting the viral spike protein—have been utilized. However, the emergence of resistant variants has created a need for novel treatments. Funded by AstraZeneca, a study was conducted to evaluate the use of sipavibart in preventing COVID-19 infection.

Potential Usage of Acetylcholine Muscarinic 1 Receptor Agonist to Manage Parkinson Disease​

Topic: NEUROLOGY
Reviewed by Dat Tien Nguyen, B.A, ScM.  
Translated by Nhi Phuong Quynh Le, B.A 
​Posted on April 2nd, 2025
Acetylcholine deficiency is linked to Parkinson’s disease and has been associated with increased stride time variability and a higher risk of falls. Normally, acetylcholine is released into the synaptic cleft to activate neighboring neurons, and its signaling is terminated by acetylcholinesterase, which degrades the neurotransmitter. However, acetylcholinesterase inhibitors have not reduced the disease burden and often lead to unacceptable side effects. To address this, a study funded by Takeda Pharmaceutical was conducted to assess TAK-071, a novel muscarinic acetylcholine 1 receptor agonist, for managing Parkinson’s disease.